EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL
The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).
- The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).
- The PASCAL system further demonstrated significant and sustained MR 1+ with 83.7 percent of patients at MR 1+ at six months.
- The CLASP IID trial is a prospective randomized controlled trial comparing the safety and effectiveness of the PASCAL system to the MitraClip system.
- Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.